July 01, 2022 – Everest Pharma proudly announces the launch of Ascimib, the FDA-approved generic version of Scemblix, marking a major advancement in the treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). Ascimib(Generic Scemblix) offers patients a more affordable and accessible alternative to the branded drug, specifically benefiting those managing Ph+ CML.
Asciminib is a tyrosine kinase inhibitor (TKI) prescribed for adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) who require systemic therapy. With the introduction of this generic treatment, Everest Pharma aims to broaden access to this innovative therapy, particularly in emerging markets where cost remains a critical barrier.
“We’re excited to introduce Ascimib as a cost-effective, FDA-approved alternative to Scemblix,” said Mr. Anwarul Hoq, CEO of Everest Pharma. “This milestone underscores our mission to provide high-quality, affordable treatments for Ph+ CMLand to address unmet healthcare needs globally.”
The availability of Ascimib(Generic Scemblix) is expected to increase competition in the pharmaceutical space, potentially lowering the overall cost of blood cancer care. Everest Pharma assures that the generic version matches the branded product in terms of safety, efficacy, and quality—ensuring confidence among physicians and patients.
As one of the first pharmaceutical companies to bring a generic version of Scemblix to market, Everest Pharma is establishing itself as a leader in delivering accessible and innovative treatments for blood cancer.
About Everest Pharma:
Everest Pharma is a globally recognized pharmaceutical company committed to offering high-quality, affordable generic medicines. With a focus on innovation and access, the company continues to develop essential therapies across a range of therapeutic areas to improve patient outcomes worldwide.
For more information on ASCIMIB and Everest Pharma’s portfolio, visit https://www.ascimib.com/ or https://www.everestpharmabd.com/
